Comparison of monoamine oxidase inhibitors in decreasing production of the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 356, Issue 2, 2016, Pages 483-492

  Goldstein, David S ^a   Jinsmaa, Yunden ^a   Sullivan, Patti ^a   Holmes, Courtney ^a   Kopin, Irwin J ^a   Sharabi, Yehonatan ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; ACETALDEHYDE; CATECHOL; CATECHOLAMINE; CLORGYLINE; CYSTEINYL DOPAMINE; DOPA; DOPAMINE; NORADRENALIN; RASAGILINE; SELEGILINE; UNCLASSIFIED DRUG; 3,4 DIHYDROXYPHENYLACETIC ACID; 3,4-DIHYDROXYPHENYLACETALDEHYDE; MONOAMINE OXIDASE INHIBITOR;

ANIMAL CELL; ARTICLE; AUTOOXIDATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG SELECTIVITY; ENZYME INHIBITION; NONHUMAN; PC12 CELL LINE; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFECTS; HUMAN; METABOLISM; PARKINSON DISEASE;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; DOPAMINE; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PC12 CELLS; RATS;

EID: 84958999128     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.230201     Document Type: Article

References (50)

1. Aguirre P, Urrutia P, Tapia V, Villa M, Paris I, Segura-Aguilar J and Nunez MT (2012) The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1. Biometals 25: 795-803.
2. Ames MM, Lerner P, and Lovenberg W (1978) Tyrosine hydroxylase. Activation by protein phosphorylation and end product inhibition. J Biol Chem 253: 27-31.
3. Anderson DG, Mariappan SV, Buettner GR, and Doorn JA (2011) Oxidation of 3,4- dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. J Biol Chem 286: 26978-26986.
4. Berman SB and Hastings TG (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease. J Neurochem 73: 1127-1137.
5. Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, Franko MW, O'Dell M, Li SW, Pan Y, and Chung HD, et al. (2008) Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 115: 193-203.
6. Burke WJ, Li SW, Williams EA, Nonneman R, and Zahm DS (2003) 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: Implications for Parkinson's disease pathogenesis. Brain Res 989: 205-213.
7. Carlsson A and Fornstedt B (1991) Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson's disease. Neurology 41(5, Suppl 2)50-51, discussion 52.
8. Carlsson A, Kehr W, and Lindqvist M (1976) The role of intraneuronal amine levels in the feedback control of dopamine, noradrenaline and 5-hydroxytryptamine synthesis in rat brain. J Neural Transm 39: 1-19.
9. Cho S, Duchemin AM, Neff NH, and Hadjiconstantinou M (1996) Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A. Eur J Pharmacol 314: 51-59.
10. de la Fuente-Fernández R, Schulzer M, Mak E, and Sossi V (2010) Trials of neuroprotective therapies for Parkinson's disease: Problems and limitations. Parkinsonism Relat Disord 16: 365-369.
11. Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, and Kopin IJ (1986) Simultaneous liquid-chromatographic determination of 3,4- dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 32: 2030-2033.
12. Eisenhofer G, Lenders JW, Harvey-White J, Ernst M, Zametkin A, Murphy DL, and Kopin IJ (1996) Differential inhibition of neuronal and extraneuronal monoamine oxidase. Neuropsychopharmacology 15: 296-301.
13. Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, and Kumar P (1978) Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology (Berl) 57: 33-38.
14. Fornstedt B and Carlsson A (1991) Effects of inhibition of monoamine oxidase on the levels of 5-S-cysteinyl adducts of catechols in dopaminergic regions of the brain of the Guinea pig. Neuropharmacology 30: 463-468.
15. Fornstedt B, Rosengren E, and Carlsson A (1986) Occurrence and distribution of 5-Scysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 25: 451-454.
16. Fowler JS, Logan J, Volkow ND, Shumay E, McCall-Perez F, Jayne M, Wang GJ, Alexoff DL, Apelskog-Torres K, and Hubbard B, et al. (2015) Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology 40: 650-657.
17. Geller AI, During MJ, Haycock JW, Freese A, and Neve R (1993) Long-term increases in neurotransmitter release from neuronal cells expressing a constitutively active adenylate cyclase from a herpes simplex virus type 1 vector. Proc Natl Acad Sci USA 90: 7603-7607.
18. Goldstein DS, Holmes C, and Sharabi Y (2012a) Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain 135: 1900-1913.
19. Goldstein DS, Kopin IJ, and Sharabi Y (2014) Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol Ther 144: 268-282.
20. Goldstein DS, Sharabi Y, Karp BI, Bentho O, Saleem A, Pacak K, and Eisenhofer G (2007) Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin Auton Res 17: 118-121.
21. Goldstein DS, Sullivan P, Cooney A, Jinsmaa Y, Sullivan R, Gross DJ, Holmes C, Kopin IJ, and Sharabi Y (2012b) Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: Relevance to the pathogenesis of Parkinson's disease. J Neurochem 123: 932-943.
22. Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R, Mash DC, Kopin IJ, and Sharabi Y (2013) Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J Neurochem 126: 591-603.
23. Goldstein DS, Udelsman R, Eisenhofer G, Stull R, Keiser HR, and Kopin IJ (1987) Neuronal source of plasma dihydroxyphenylalanine. J Clin Endocrinol Metab 64: 856-861.
24. Gordon SL, Quinsey NS, Dunkley PR, and Dickson PW (2008) Tyrosine hydroxylase activity is regulated by two distinct dopamine-binding sites. J Neurochem 106: 1614-1623.
25. Holford NH and Nutt JG (2011) Interpreting the results of Parkinson's disease clinical trials: Time for a change. Mov Disord 26: 569-577.
26. Holmes C, Eisenhofer G, and Goldstein DS (1994) Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 653: 131-138.
27. Horwitz D, Lovenberg W, Engelman K, and Sjoerdsma A (1964) Monoamine oxidase inhibitors, tyramine, and cheese. JAMA 188: 1108-1110.
28. Hovevey-Sion D, Kopin IJ, Stull RW, and Goldstein DS (1989) Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma. Neuropharmacology 28: 791-797.
29. Karobath M (1971) Catecholamines and the hydroxylation of tyrosine in synaptosomes isolated from rat brain. Proc Natl Acad Sci USA 68: 2370-2373.
30. Kish SJ, Shannak K, and Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318: 876-880.
31. Kvetnansky R, Armando I, Weise VK, Holmes C, Fukuhara K, Deka-Starosta A, Kopin IJ, and Goldstein DS (1992) Plasma dopa responses during stress: Dependence on sympathoneural activity and tyrosine hydroxylation. J Pharmacol Exp Ther 261: 899-909.
32. Lamensdorf I, Eisenhofer G, Harvey-White J, Hayakawa Y, Kirk K, and Kopin IJ (2000) Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J Neurosci Res 60: 552-558.
33. Laschinski G, Kittner B, and Bräutigam M (1986) Direct inhibition of tyrosine hydroxylase from PC-12 cells by catechol derivatives. Naunyn Schmiedebergs Arch Pharmacol 332: 346-350.
34. Lenders JWM, Eisenhofer G, Abeling NGGM, Berger W, Murphy DL, Konings CH, Wagemakers LMB, Kopin IJ, Karoum F, and van Gennip AH, et al. (1996) Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J Clin Invest 97: 1010-1019.
35. Lenzen S, Freisinger-Treichel M, and Panten U (1987) Monoamine oxidase in rat and bovine endocrine tissues. J Neurochem 49: 1183-1190.
36. Linsenbardt AJ, Wilken GH, Westfall TC, and Macarthur H (2009) Cytotoxicity of dopaminochrome in the mesencephalic cell line, MN9D, is dependent upon oxidative stress. Neurotoxicology 30: 1030-1035.
37. Löhle M and Storch A (2008) Orally disintegrating selegiline for the treatment of Parkinson's disease. Expert Opin Pharmacother 9: 2881-2891.
38. Lohr KM, Bernstein AI, Stout KA, Dunn AR, Lazo CR, Alter SP, Wang M, Li Y, Fan X, and Hess EJ, et al. (2014) Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc Natl Acad Sci USA 111: 9977-9982.
39. McCann H, Cartwright H, and Halliday GM (2015) Neuropathology of a-synuclein propagation and braak hypothesis. Mov Disord 10.1002/mds.26421.
40. Mexas LM, Florang VR, and Doorn JA (2011) Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite. Neurotoxicology 32: 471-477.
41. Montine TJ, Picklo MJ, Amarnath V, Whetsell WO, Jr, and Graham DG (1997) Neurotoxicity of endogenous cysteinylcatechols. Exp Neurol 148: 26-33.
42. Mosharov EV, Staal RG, Bové J, Prou D, Hananiya A, Markov D, Poulsen N, Larsen KE, Moore CM, and Troyer MD, et al. (2006) Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci 26: 9304-9311.
43. Panneton WM, Kumar VB, Gan Q, Burke WJ, and Galvin JE (2010) The neurotoxicity of DOPAL: Behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One 5: E15251.
44. Pifl C, Rajput A, Reither H, Blesa J, Cavada C, Obeso JA, Rajput AH, and Hornykiewicz O (2014) Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. J Neurosci 34: 8210-8218.
45. Raffel DM and Wieland DM (1999) Influence of vesicular storage and monoamine oxidase activity on [11C]phenylephrine kinetics: Studies in isolated rat heart. J Nucl Med 40: 323-330.
46. Spencer JP, Whiteman M, Jenner P, and Halliwell B (2002) 5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J Neurochem 81: 122-129.
47. Sun M, Kong L, Wang X, Holmes C, Gao Q, Zhang GR, Pfeilschifter J, Goldstein DS, and Geller AI (2004) Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease. Hum Gene Ther 15: 1177-1196.
48. Thébault JJ, Guillaume M, and Levy R (2004) Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: A potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy 24: 1295-1305.
49. Wallace LJ (2007) A small dopamine permeability of storage vesicle membranes and end product inhibition of tyrosine hydroxylase are sufficient to explain changes occurring in dopamine synthesis and storage after inhibition of neuron firing. Synapse 61: 715-723.
50. Youdim MB and Weinstock M (2004) Therapeutic applications of selective and nonselective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology 25: 243-250.